Loading...

News List

司美格鲁肽迎来真正对手!礼来最强减肥药替尔泊肽获FDA批准上市

2023-11-30


美国FDA批准了礼来公司开发的替尔泊肽(Tizepatide)作为减肥药物上市(商品名Zepbound™),适用于肥胖(BMI在30及以上)或超重(BMI在27以上,但伴有至少一种体重相关合并症,例如高血压、2型糖尿病或高胆固醇)的成年人减肥,与降低饮食热量和增加运动一起管理体重。Tizepatide是礼来开发的一款葡萄糖依赖性促胰岛素多肽(GIP)受体和胰高血糖素样肽-1(GLP-1)受体的双重激动剂,能够对食欲、热量摄入和代谢功能产生协同作用。此次获批用于减肥后,其成为第一个也是目前唯一一个用于减肥的同时激活两种肠促胰岛素激素受体的治疗方法。


Pre: It can restore 80% hair growth, and Pfizer's new drug for alopecia areata was approved for sale in China, which can treat adolescent alopecia areata

Next: Semaglutide has a real rival! Lilly's strongest weight-loss drug, tilpotide is approved by the FDA

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.